Tim Lohoff PhD
Principal
Slate Medicines is a biotech company focused on developing next generation therapeutics targeting PACAP for the treatment and prevention of migraine and other headache disorders.
The company’s lead program, SLTE-1009, is a potential best-in-class subcutaneous anti-PACAP for the prevention of migraine and other headache disorders.
Industry
Biotech
Year Invested
2026
Status
Current
Location
Raleigh, North Carolina
$245M
financing expected to fund Slate Medicines’ next-generation migraine pipeline into 2029
Forbion team
Rogier Rooswinkel PhD
General Partner
Vincent Loon MSc
Analyst
Luuk de Vries PhD
Senior Analyst
Nat Kolber PhD
Analyst